Indication

Prurigo nodularis

Prurigo nodularis is a chronic, inflammatory neuroimmune dermatologic disorder that most commonly affects middle-aged to older adults and individuals with atopic diathesis or chronic pruritic systemic conditions. Read more about Prurigo nodularis

4 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Prurigo nodularis therapies.

Showing 1–4 of 4 drugs

DUPIXENT (dupilumab)

ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.

DUPIXENT PEN (dupilumab)

ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.
Filter & compare in the drug finder →Opens the drug finder with Prurigo nodularis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prurigo nodularis.

Prurigo nodularis is a chronic, inflammatory neuroimmune dermatologic disorder that most commonly affects middle-aged to older adults and individuals with atopic diathesis or chronic pruritic systemic conditions.

It is clinically characterized by the development of multiple, firm, intensely pruritic, hyperkeratotic papules and nodules that typically exhibit a symmetric distribution over the extensor surfaces of the limbs and the trunk.

Pathophysiologically, the disease is sustained by a dysregulated itch-scratch cycle involving complex neuroimmune crosstalk, characterized by cutaneous neural hyperplasia, local release of neuropeptides, and type 2 helper T-cell-mediated cytokine signaling that drives recalcitrant neurogenic inflammation and epidermal thickening.

Personalize your experience

Follow Prurigo nodularis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it